Abstracts tagged "patient-reported outcome measures"

Abstract Number: 1108 • 2019 ACR/ARP Annual Meeting
Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Johannes Knitza¹, Koray Tascilar ², Eva-Maria Messner ³, Marco Meyer ⁴, Diana Vossen ⁵, Almut Pulla ⁶, Philipp Bosch ⁷, Julia Kittler ⁸, Arnd Kleyer ¹, Philipp Sewerin ⁹, Johanna Mucke ¹⁰, Isabell Haase ¹¹, David Simon ¹² and Martin Krusche ¹³, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department for Clinical Psychology and Psychotherapy, Ulm University, Ulm, Germany, Ulm, Germany, ⁴Asklepios Klinik Altona, Rheumatologie, Klinische Immunologie, Nephrologie, Hamburg, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Hamburg, Germany, ⁵Departement for Internal Medicine and Rheumatology, Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁶Rheinisches Rheumazentrum Meerbusch, St. Elisabeth-Hospital, Meerbusch, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Meerbusch, Germany, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Erlangen, Germany, ⁹Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ¹⁰Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Düsseldorf, Germany, ¹¹Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ¹³Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin, Berlin, Germany; German Society for Rheumatology (Working Group Young Rheumatology), Berlin, Germany
Background/Purpose: Mobile applications promise to facilitate the life of patients as well as physicians. In routine practice, however, rheumatology apps are largely unknown and little…
Abstract Number: 1209 • 2019 ACR/ARP Annual Meeting
Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice – Preliminary Results from the Integrate Project
Gamal Chehab¹, Jutta Richter ², Anna Kernder ¹, Chiara Tani ³, Valentina Lorenzoni ⁴, Elena Elefante ³, Ilaria Palla ⁵, Sara Cannizzo ⁶, Salvatore Pirri ⁶, Isotta Triulzi ⁵, Leopoldo Trieste ⁵, Giuseppe Turchetti ⁵, Marta Mosca ³ and Matthias Schneider ⁷, ¹Policlinic of Rheumatology and Hiller Research Unit Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ²Department and Hiller Research Unit of Rheumatology, Heinrich-Heine University Duesseldorf, Duesseldorf, Nordrhein-Westfalen, Germany, ³Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, ⁴Institute of Management , Scuola Superiore Sant'Anna, Pisa, Italy, ⁵Institute of Management, Scuola Superiore Sant'Anna, Pisa, Italy, ⁶Institute of Management, Scuola Superiore Sant'Anna, Pisa, Toscana, Italy, ⁷Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: Due to improved mortality and morbidity in systemic lupus erythematosus (SLE), non-clinical indicators and outcomes, especially patient-reported ones, have become increasingly important in disease…
Abstract Number: 329 • 2018 ACR/ARHP Annual Meeting
Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Elisheva Weinberger¹, Douglas Einstadter² and Marina Magrey¹, ¹Rheumatology, Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH, ²Case Western Reserve University at MetroHealth Medical Center, Cleveland, OH
Background/Purpose: “Treat to target” is the goal of therapy in the treatment of Rheumatoid Arthritis (RA) based on the 2015 American College of Rheumatology (ACR)…
Abstract Number: 549 • 2018 ACR/ARHP Annual Meeting
Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Dimitrios A. Pappas^1,2, Namita Tundia³, Ying Shan², Heather J Litman² and Joel Kremer⁴, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Targeted immunomodulators (TIMs) have revolutionized the therapy of RA and made low disease activity (LDA) a realistic goal for patients. Given the multiple therapy…
Abstract Number: 892 • 2018 ACR/ARHP Annual Meeting
Establishing the Minimal Clinically Important Difference (MCID) for the Ankylosing Spondylitis Quality of Life Questionnaire (ASQoL)
Nicolas Richard¹, Nigil Haroon², George Tomlinson³, Ismail Sari¹, Zahi Touma⁴ and Robert D Inman¹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The Ankylosing Spondylitis Quality of Life (ASQoL) is a readable and simple to complete questionnaire relating to health-related quality of life (HRQoL) in subjects…
Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting
Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients
Jens Gert Kuipers¹, Michael Koller², Ulrich Rueffer³, Florian Zeman², Karolina Mueller⁴ and Joachim Weis⁵, ¹Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³German Fatigue Society, Cologne, Germany, ⁴Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁵University Clinic Centre Freiburg, Freiburg, Germany
Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1715 • 2018 ACR/ARHP Annual Meeting
Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Robert F. Spiera¹, Laura K. Hummers², Lorinda Chung³, Tracy M. Frech⁴, Robyn T. Domsic⁵, Vivien Hsu⁶, Daniel E. Furst⁷, Jessica K. Gordon¹, Maureen D. Mayes⁸, Robert W. Simms⁹, Elizabeth Lee¹⁰, Scott Constantine¹⁰ and Barbara White¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁴Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology, Robert Wood Johnson Medical School, New Brunswick, NJ, ⁷Pacific Arthritis Associates, Los Angeles; University of California, Los Angeles; University of Washington, Seattle; University of Florence, Italy, Los Angeles, CA, ⁸Rheumatology, University of Texas McGovern Medical School, Houston, TX, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Corbus Pharmaceuticals, Inc., Norwood, MA
Background/Purpose: Lenabasum is a synthetic, non-immunosuppressive, selective cannabinoid receptor type 2 agonist that activates resolution of innate immune responses. Lenabasum had acceptable safety and tolerability,…
Abstract Number: 2480 • 2018 ACR/ARHP Annual Meeting
Patient-Reported Outcome Measures Used in Rheumatoid Arthritis Cohorts and Registries Around the World: An Environmental Scan from the Outcome Measures in Rheumatology Critical Outcomes in Longitudinal Observational Studies Working Group
Richard Zogala¹, Karla Criner², Maria A. Lopez-Olivo¹, Natalia Zamora³, Devesh Rai¹, Gregory Pratt⁴, Jude K. A. des Bordes¹, Robin Christensen⁵ and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Internal Medicine, Baylor College of Medicine, Houston, TX, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁴Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁵Department of Rheumatology, Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, & Department of Rheumatology, Odense University Hospital, Copenhagen, Denmark
Background/Purpose: International registries and cohorts could potentially provide long-term data on patient-centered outcomes. In recent years there has been a concerted effort to define a…
Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting
Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE
Rebecca Heijke¹, Mathilda Björk¹, Martina Frodlund¹, Laura McDonald², Evo Alemao³ and Christopher Sjöwall¹, ¹Linköping University, Linköping, Sweden, ²Bristol-Myers Squibb, Uxbridge, United Kingdom, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
Abstract Number: 1080 • 2017 ACR/ARHP Annual Meeting
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver Satisfaction
Y. Ingrid Goh¹, Talia Goldberg², Nicholas Lao³ and Brian M. Feldman⁴, ¹Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Electronic Patient Reported Outcomes Increase Pediatric Rheumatology Clinic Operations Efficiency While Increasing Patient and Caregiver SatisfactionBackground/Purpose: Patient reported outcomes (PROs) are powerful tools that facilitate…
Abstract Number: 1081 • 2017 ACR/ARHP Annual Meeting
Improving Patient-Reported Outcomes Collection and Documentation for Patients with Rheumatoid Arthritis at Multilingual, Safety Net Hospital Rheumatology Clinic
Todd Liou¹, Omotoke Odimayomi¹, Laura Trupin², Jinoos Yazdany² and Mary Margaretten³, ¹University of California San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Medicine, University of California San Francisco, San Francisco, CA
Background/Purpose: The Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function-10a (PF10a) survey is a reliable and valid measure of function in patients with rheumatoid arthritis…
Abstract Number: 1235 • 2017 ACR/ARHP Annual Meeting
Perceived Stress and Fatigue in Systemic Lupus Erythematosus
Patricia P. Katz¹, Desiree R Azizoddin² and Meenakshi Jolly³, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Department of Medicine and Behavioral Sciences, Rush University, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Fatigue is a common and often severe symptom among individuals with systemic lupus erythematosus (SLE). Yet, there is an incomplete understanding of the causes…
Abstract Number: 1476 • 2017 ACR/ARHP Annual Meeting
Effect of Treat-to-Target Tocilizumab- and Methotrexate-Based Strategies on Health-Related Quality of Life in Newly Diagnosed Rheumatoid Arthritis Patients: Results of the U-Act-Early Trial
Xavier M Teitsma¹, Johannes WG Jacobs¹, Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Jacob M. van Laar⁵, Floris PJ Lafeber⁵ and Johannes W.J. Bijlsma², ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Beneluxlaan 2a, Roche Nederland BV, Woerden, Netherlands, ⁵Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Patient-reported outcomes are, in addition to other efficacy and safety related outcomes, important reflections of effectiveness and adverse effects of a therapy. The Outcomes…
Abstract Number: 1477 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes As Independent Measures of Treatment Success with Sirukumab, an Anti-IL6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Post-Hoc Analysis of 2 Placebo-Controlled Phase 3 Trials
Vibeke Strand¹, Rita Ganguly², Nan Li³, Prasheen Agarwal³, Shihong Sheng³, Kaiyin Fei³, Kelly McQuarrie³ and Sharon Popik³, ¹Division of Immunology/Rheumatology, Stanford University, Stanford, CA, ²GlaxoSmithKline, Collegeville, PA, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Sirukumab, a selective, high-affinity, human anti–IL-6 monoclonal antibody, is in development for rheumatoid arthritis (RA) and other diseases. Effects of sirukumab on RA symptoms…